Close the Gap in Dementia Detection and Care

Creyos has been validated as a more scalable and efficient alternative to neuropsychological testing, providing detailed insights into specific cognitive domains in a fraction of the time required for a full neuropsychological battery. Its tasks have demonstrated strong correlations with gold-standard neuropsychological tests, offering high convergent validity and supporting its use as an informative follow-up to initial screening.

Yes—Creyos is specifically designed to detect subtle cognitive changes often missed by screening tools like the MoCA or MMSE. It measures multiple domains, including memory and executive function, to help identify early decline, even if it has not yet affected everyday tasks or responses to simple screeners. A series of recent studies provide compelling support for integrating Creyos assessments into routine cognitive evaluations and leveraging it as an alternative to the MoCA or MMSE.

Creyos supports Medicare requirements by streamlining both cognitive assessment and care planning in a single platform. It enables fast, standardized cognitive testing as part of the Annual Wellness Visit (AWV), helping providers efficiently meet documentation requirements while identifying early signs of impairment. This is especially important under CMS-HCC V28, where a timely and accurate dementia diagnosis contributes to appropriate risk adjustment and care management.

Beyond assessment, Creyos offers built-in care plan creation to guide next steps for both the provider and patient. Clinicians use the results from the Creyos dementia assessment to document personalized care plans, including recommendations for follow-up testing, behavioral health support, medication management, caregiver guidance, and lifestyle modifications—ensuring compliance with Medicare expectations, while supporting better outcomes across the care continuum.

Yes. Creyos helps providers identify signs of dementia that traditional screening tools often miss and supports the diagnostic specificity required under CMS-HCC V28.

Using a sensitive, scientifically validated digital screener and assessment, Creyos detects cognitive impairment across a full range of severity—from mild to moderate to severe. This enables earlier identification and more accurate differentiation of dementia stages, which is essential for compliant and specific coding under V28.

Creyos helps health systems detect dementia earlier and more often—typically increasing detection rates from the typical 4-6% to 8-12% of their 65+ patient population. That translates to significantly more patients receiving timely diagnoses and care, and a meaningful financial impact: each additional diagnosis can add roughly $2,400 per member in RAF-adjusted reimbursement annually.

Early detection also leads to better care planning and fewer high cost events. Studies show that people with undiagnosed dementia are up to two times more likely to be hospitalized, and account for up to 40% higher healthcare costs. With Creyos, providers can intervene earlier—reducing preventable hospitalizations and ER visits, all of which lower total cost of care and support quality metrics around screening, care coordination, and chronic condition management.